oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Search Results: 1 - 10 of 688 matches for " Bill Baritompa "
All listed articles are free for downloading (OA Articles)
Page 1 /688
Display every page Item
Mathematical table turning revisited
Bill Baritompa,Rainer L"owen,Burkard Polster,Marty Ross
Mathematics , 2005,
Abstract: We investigate under which conditions a rectangular table can be placed with all four feet touching a continuous ground by turning it on the spot.
Not All “BAD” Cholesterol Carriers Are Necessarily Bad and Not All “GOOD” Cholesterol Carriers Are as Good as Can Be: Plasma Delipidation, a Non-Pharmacological Treatment for Atherosclerosis  [PDF]
Bill Cham
International Journal of Clinical Medicine (IJCM) , 2015, DOI: 10.4236/ijcm.2015.69092
Abstract: More than four decades ago it was established that an elevated low-density lipoprotein-cholesterol level was a risk for developing coronary artery disease. For the last two decades, statins have been the cornerstone of reducing low-density lipoprotein-cholesterol, but despite significant clinical efficacy in the majority of patients, a large number of patients suffer from side effects and cannot tolerate the required statin dose to reach their recommended low-density lipoprotein-cholesterol goals. Preliminary clinical studies indicate that monoclonal antibodies to PCSK9 appear to be highly efficacious in lowering low-density lipoprotein-cholesterol with a favourable adverse event profile. However, further longer-term clinical studies are required to determine their safety. From the early-proposed concept for high-density lipoprotein-mediated cholesterol efflux for the treatment of coronary artery disease, the concentration of the cholesterol content in high-density lipoprotein particles has been considered a surrogate measurement for the efficacy of the reverse cholesterol transport process. However, unlike the beneficial effects of the statins and monoclonal antibodies to PCSK9 in reducing low-density lipoprotein-cholesterol, no significant advances have been made to increase the levels of high-density lipoprotein-cholesterol. Here it is shown that by a non-pharmacological plasma delipidation means, the atherogenic low-density lipoproteins can be converted to anti-atherogenic particles and that the high-density lipoproteins are converted to particles with extreme high affinity to cause rapid regression of atherosclerosis.
Topical Solasodine Rhamnosyl Glycosides Derived From the Eggplant Treats Large Skin Cancers: Two Case Reports  [PDF]
Bill E. Cham
International Journal of Clinical Medicine (IJCM) , 2011, DOI: 10.4236/ijcm.2011.24080
Abstract: Solasodine rhamnosyl glycosides (BEC) are a new class of antineoplastics that show superior efficacy than many established anticancer drugs as shown by intravenous, intraperitoneal and intralesion administrations. Previous studies have described the efficacy of BEC on nonmelanoma skin cancers by topical application. Two cases are now reported which show that BEC in a cream formulation Curaderm is very effective for the treatment of large nonmelanoma skin cancers that are considered difficult to treat by existing modalities. Moreover, the cosmetic outcomes are very impressive.
General Purpose Wireless Communication System Using Data Acquisition  [PDF]
Abdullah Eroglu, Bill Westrick
Communications and Network (CN) , 2012, DOI: 10.4236/cn.2012.41007
Abstract: A sensor-enabled and RFID-integrated, Wireless Data Acquisition System (WDAS) that has similar functionality as multiple input multiple output (MIMO) systems for health-care applications has been developed, simulated and implemented. The system can accept various measurements via sensors placed on patients or elders and transmit information wirelessly to base station at a remote location. A microcontroller is used to control and process the signals submitted from sensor-enabled RFID devices using sequential logic. Processed signals are then sent to single receiver and transmitter pair instead of conventional MIMO antenna systems. This reduces the cost significantly in comparison to existing systems. It has been shown that the data transmitted from measurement locations can be acquired at the base station located 20 mile away. Data acquisition system (DAQ) is used to determine the measured value, apply the required statistics and display information to health-care professional at the base station. The system developed can be used for health-care applications including nursing homes in rural areas where access is difficult.
Intralesion and CuradermBEC5 Topical Combination Therapies of Solasodine Rhamnosyl Glycosides Derived from the Eggplant or Devil’s Apple Result in Rapid Removal of Large Skin Cancers. Methods of Treatment Compared  [PDF]
Bill E. Cham
International Journal of Clinical Medicine (IJCM) , 2012, DOI: 10.4236/ijcm.2012.32024
Abstract: Solasodine rhamnosyl glycosides (SRGs) are chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation, CuradermBEC5, is very effective for the treatment of nonmelanoma skin cancers with excellent cosmetic end results. Intralesion injection of SRGs successfully dispose of very large tumours in animals without any clinical adverse effects. The mode of action of SRGs is by apoptosis. In this study, it is shown that small to large basal cell carcinomas are effectively treated only with topical application of CuradermBEC5. Here it is reported for the first time that combination of intralesion SRG injection and topical application with CuradermBEC5 in humans reduces the treatment time period by more than half when compared with topical application as the sole treatment regime. Two intralesion injections of very low doses of SRGs rapidly and effectively remove a large melanoma on a horse. If rapid removal of large troublesome skin cancers is required then this can be achieved by intralesion and topical treatments. Intralesion or combination therapy with SRGs may have some applications for melanomas in situ such as lentigo maligna.
Drug therapy: Solamargine and other solasodine rhamnosyl glycosides as anticancer agents  [PDF]
Bill E. Cham
Modern Chemotherapy (MC) , 2013, DOI: 10.4236/mc.2013.22005
Abstract:

In the last century, the discovery of cytotoxic agents was revolutionary for anticancer therapy. These therapies have resulted in better understanding of cancer in general. However, the development of agents that combine efficacy, safety and convenience remains a great challenge. The narrow, if not adverse, therapeutic index of most drugs, the damage not only to cancer cells, but also to normal and healthy tissue and the occurrence of resistance have limited anticancer efficacy. This review presents the development of promising novel cytotoxic solasodine rhamnosyl glycoside drugs that offer not only gains in specificity and efficacy, but also in safety, tolerability, non-resistance and convenience in the treatment of patients with cancer.

Topical CuradermBEC5 Therapy for Periocular Nonmela-noma Skin Cancers: A Review of Clinical Outcomes  [PDF]
Bill E. Cham
International Journal of Clinical Medicine (IJCM) , 2013, DOI: 10.4236/ijcm.2013.45041
Abstract:
Approximately 5 to 10 percent of all skin cancers occur in the periocular region. Basal cell carcinoma is the most frequent malignant periocular tumor, followed by squamous cell carcinoma, sebaceous gland carcinoma, and malignant melanoma. Nonmelanoma skin tumors at the periocular area often cause disfigurement with destruction of soft conjunctival tissue. Many therapeutic methods have been recommended to combat the morbidity and mortality associated with these lesions. Excisions with frozen-section control or Mohs micrographic surgery are regarded as the gold-standard treatments for periocular basal cell and squamous cell carcinomas. However, these treatment modalities have various limitations and reconstruction surgery is often associated with these treatment options. The chemotherapeutic agents solasodine rhamnosides in a cream formulation CuradermBEC5 are specific, effective and safe treatments for nonmelanoma skin cancers with excellent cosmesis. The antineoplastic mode of action is by apoptosis. In this review it is shown that CuradermBEC5 also treats periocular basal cell carcinoma and squamous cell carcinoma with impressive cosmetic outcomes and no reconstructive surgery is required.
Solasodine Glycosides: A Topical Therapy for Actinic Keratosis. A Single-Blind, Randomized, Placebo-Controlled, Parallel Group Study with CuradermBEC5  [PDF]
Bill E. Cham
Journal of Cancer Therapy (JCT) , 2013, DOI: 10.4236/jct.2013.42076
Abstract:


Background: Untreated actinic keratosis can advance to squamous cell carcinoma, which in turn is associated with a risk of metastasis. Current treatments for actinic keratosis have many shortcomings. This communication describes the efficacy and safety of a topical cream therapy, CuradermBEC5, containing solasodine glycosides (0.005%) for actinic keratosis.Methods: Randomly assigned patients with actinic keratosis on the face, trunk or extremities received so-lasodine glycosides cream (CuradermBEC5) or placebo (vehicle) that was self-applied to the lesions and covered with an occlusive dressing (micropore) twice daily for 3 consecutive days. Complete clearance and local reactions were as-sessed at 56 days with follow-up periods of 6 months and 1 year. Results: The rate of complete clearance at day 56 was higher with solasodine glycosides than with placebo (92% vs. 38%, P < 0.001). The absolute success rates after 1 year follow-up were 82% for solasodine glycosides and 18% for placebo. No differences in local reactions were obtained when solasodine glycosides and placebo were compared. Local reactions in both groups peaked at days 2 and 3 with local pain as the major event. The pain associated with treatments lasted approximately 10 minutes after application of solasodine

Using ScalIT for Performing Accurate Rovibrational Spectroscopy Calculations for Triatomic Molecules: A Practical Guide  [PDF]
Corey Petty, Bill Poirier
Applied Mathematics (AM) , 2014, DOI: 10.4236/am.2014.517263
Abstract: This paper presents a practical guide for use of the ScalIT software package to perform highly accurate bound rovibrational spectroscopy calculations for triatomic molecules. At its core, ScalIT serves as a massively scalable iterative sparse matrix solver, while assisting modules serve to create rovibrational Hamiltonian matrices, and analyze computed energy levels (eigenvalues) and wavefunctions (eigenvectors). Some of the methods incorporated into the package include: phase space optimized discrete variable representation, preconditioned inexact spectral transform, and optimal separable basis preconditioning. ScalIT has previously been implemented successfully for a wide range of chemical applications, allowing even the most state-of-the-art calculations to be computed with relative ease, across a large number of computational cores, in a short amount of time.
Treatment of Skin Cancer with a Selective Apoptotic-Inducing CuradermBEC5 Topical Cream Containing Solasodine Rhamnosides  [PDF]
Aruba Cham, Bill Cham
International Journal of Clinical Medicine (IJCM) , 2015, DOI: 10.4236/ijcm.2015.65042
Abstract:
Solasodine rhamnosides produced in plants as secondary metabolites, are safe and effective when treating a variety of cancers, including non-melanoma skin cancers. They are cytotoxic against multi-drug resistant tumor cells, stimulate lasting immunity against cancer, are not mutagenic and display anti-mutagenic properties. These antineoplastics, through cellular specific receptor-mediated actions, directly induce apoptosis by triggering extrinsic and intrinsic apoptotic pathways in cancer cells but not normal cells. CuradermBEC5 contains solasodine rhamnosides and is a topical formulation for the treatment of keratoses and non-melanoma skin cancers. The mode of action, together with the selectivity towards cancer cells, with CuradermBEC5 therapy, results in outstanding beneficial outcomes. This study shows graphically and pictorially that CuradermBEC5 seeks and destroys basal cell carcinoma whilst normal skin cells replace the dead cancer cells during therapy, emanating into impressive cosmetic end results. The clinical observations with CuradermBEC5 therapy reveal that initially the lesion size increases over four-fold due to the interaction of CuradermBEC5 with deeper and more lateral tumor cells, followed by a decrease in size, ultimately, resulting in complete elimination of the basal cell carcinoma.
Page 1 /688
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.